Camp4 Therapeutics annual revenue
2022
2023
2024
2025
Camp4 Therapeutics Revenue Growth & History (CAMP)
Camp4 Therapeutics reported $3.5M in revenue for fiscal 2025, an increase of 436.50% from the previous fiscal year.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.5M | $2.8M | +436.50% |
| 2024 | 2024-12-31 | $652,000 | $302,000 | +86.29% |
| 2023 | 2023-12-31 | $350,000 | $350,000 | — |
| 2022 | 2022-12-31 | $0 | — | — |
Camp4 Therapeutics quarterly revenue
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | $282,000 | +18.84% |
| Q1 2026 | 2026-03-31 | $1.3M | $436,000 | +50.82% |
| Q4 2025 | 2025-12-31 | $348,000 | −$304,000 | −46.63% |
| Q3 2025 | 2025-09-30 | $795,000 | $795,000 | — |
| Q2 2025 | 2025-06-30 | $1.5M | $1.5M | — |
| Q1 2025 | 2025-03-31 | $858,000 | $858,000 | — |
| Q4 2024 | 2024-12-31 | $652,000 | — | — |
| Q3 2024 | 2024-09-30 | $0 | −$350,000 | −100.00% |
| Q2 2024 | 2024-06-30 | $0 | — | — |
| Q1 2024 | 2024-03-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $350,000 | — | — |
Camp4 Therapeutics revenue growth trends
Camp4 Therapeutics's latest reported quarter, Q2 2026, generated $1.8M in revenue, an increase of 18.84% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...
